Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

Xin He(Nanjing Drum Tower Hospital), Liansheng Huang(Second Affiliated Hospital of Zhejiang University), Yun Liang(Shandong University of Traditional Chinese Medicine), Tao Fu, Xueli Jin(Second Affiliated Hospital of Zhejiang University), Teng Yu(Ministry of Education of the People's Republic of China), Xiaoying Zhao(Handan College), Zhigang Chen(China Pharmaceutical University)
BMC Cancer
March 5, 2014
10.1186/1471-2407-14-153
Cited by 146

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247
Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis
|PLoS ONE|2015|115
Clinical and biological significance of<i>de novo</i>CD5+ diffuse large B-cell lymphoma in Western countries
|Oncotarget|2015|93